Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Patry, the most common co-covered peer. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window.
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Patry, the most common co-covered peer. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window. Their average consequence score of 6 runs below the beat's 6.3 for that window. BioCina appears in 1 tracked Biotech story from March 17, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering BioCina. Shared-story counts are live from our verified record — not editorial picks.
BioCina has initiated a comprehensive manufacturing program for Patry, a proprietary injectable therapeutic designed to alleviate delirium. This partnership marks a critical transition from clinical development to scalable production, leveraging BioCina's specialized microbial fermentation capabilities.
BioCina is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
